Premium
Crocin and crocetin derivatives inhibit skin tumour promotion in mice
Author(s) -
Konoshima T.,
Takasaki M.,
Tokuda H.,
Morimoto S.,
Tanaka H.,
Kawata E.,
Xuan L. J.,
Saito H.,
Sugiura M.,
Molnar J.,
Shoyama Y.
Publication year - 1998
Publication title -
phytotherapy research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.019
H-Index - 129
eISSN - 1099-1573
pISSN - 0951-418X
DOI - 10.1002/(sici)1099-1573(199809)12:6<400::aid-ptr321>3.0.co;2-4
Subject(s) - crocin , crocetin , dmba , crocus sativus , chemistry , pharmacology , anticarcinogen , iridaceae , tumor promotion , biochemistry , carcinogenesis , in vitro , medicine , traditional medicine , biological activity , biology , botany , gene
Abstract The addition of 100 μg/mL of a 50% EtOH extract of Crocus sativus (ECS) exhibited significant inhibitory effects on EBV‐EA activation and preserved the high viability of Raji cells. The attenuating effect of ECS was dose‐dependent. The oral administration of ECS demonstrated an inhibitory effect on two‐stage carcinogenesis of mouse skin papillomas, using DMBA as an initiator and TPA as a promoter. Crocetin gentiobiose glucose ester and crocetin di‐glucose ester were less potent than crocin in inhibiting the EBV‐EA induction effect. When crocin was applied before each TPA treatment, it delayed the formation of papillomas; only about 10% of mice bore papillomas at 9 weeks of promotion and after 13 weeks of promotion 20% of mice still bore no papilloma. The effect of crocin was not mimicked by gentiobiose or glucose alone. © 1998 John Wiley & Sons, Ltd.